PriceTargets.com logo

Nuvectis Pharma - NVCT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.00
  • Forecasted Upside: 220.12%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$6.56 As of 04/18/2024 03:36 PM ET
▼ -0.2 (-2.96%)

This chart shows the closing price for NVCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nuvectis Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVCT

Analyst Price Target is $21.00
▲ +220.12% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Nuvectis Pharma in the last 3 months. The average price target is $21.00, with a high forecast of $21.00 and a low forecast of $21.00. The average price target represents a 220.12% upside from the last price of $6.56.

This chart shows the closing price for NVCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Nuvectis Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$21.00Low
3/7/2023HC WainwrightReiterated RatingBuy$21.00Low
2/10/2023HC WainwrightReiterated RatingBuy$21.00Low
7/13/2022LADENBURG THALM/SH SHInitiated CoverageBuy$21.00N/A
5/10/2022HC WainwrightBoost Target$14.00 ➝ $21.00Low
4/17/2022Roth CapitalReiterated RatingBuyLow
4/13/2022HC WainwrightReiterated RatingBuy$14.00Low
3/2/2022HC WainwrightInitiated CoverageBuy$14.00Medium
(Data available from 4/18/2019 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/19/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 6 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Nuvectis Pharma logo
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Read More

Today's Range

Now: $6.56
Low: $6.56
High: $7.06

50 Day Range

MA: $8.46
Low: $6.41
High: $11.00

52 Week Range

Now: $6.56
Low: $6.20
High: $18.65

Volume

49,065 shs

Average Volume

99,918 shs

Market Capitalization

$116.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Nuvectis Pharma?

The following Wall Street research analysts have issued research reports on Nuvectis Pharma in the last year: HC Wainwright.
View the latest analyst ratings for NVCT.

What is the current price target for Nuvectis Pharma?

1 Wall Street analysts have set twelve-month price targets for Nuvectis Pharma in the last year. Their average twelve-month price target is $21.00, suggesting a possible upside of 220.1%. HC Wainwright has the highest price target set, predicting NVCT will reach $21.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $21.00 for Nuvectis Pharma in the next year.
View the latest price targets for NVCT.

What is the current consensus analyst rating for Nuvectis Pharma?

Nuvectis Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NVCT will outperform the market and that investors should add to their positions of Nuvectis Pharma.
View the latest ratings for NVCT.

What other companies compete with Nuvectis Pharma?

Other companies that are similar to Nuvectis Pharma include Repare Therapeutics, OptiNose, Vistagen Therapeutics, CytomX Therapeutics and Eliem Therapeutics. Learn More about companies similar to Nuvectis Pharma.

How do I contact Nuvectis Pharma's investor relations team?

The company's listed phone number is 201-614-3150. The official website for Nuvectis Pharma is www.nuvectis.com. Learn More about contacing Nuvectis Pharma investor relations.